TP53 and myelodysplastic syndrome: This analysis showed that TP53-mutant MDS patients can be subdivided into three groups according to blast cell counts: <5% (24% with multi-hit TP53 alterations), 5–10% (67% multi-hit TP53 alterations) and 5–19% (91% multi-hit TP53 alterations, with a mOS of 17, 10 and 8 months, respectively [17].